Cargando…

The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder

Introduction: Major depressive disorder (MDD) is the leading cause of disability worldwide, and according to the STAR*D trial, only 33% of patients with MDD responded to initial drug therapy. Augmentation of the leading class of antidepressant treatment, selective serotonin reuptake inhibitors (SSRI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahli, Zeyad T., Banerjee, Pradeep, Tarazi, Frank I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Drug Discovery Case History
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841022/ https://www.ncbi.nlm.nih.gov/pubmed/26971593 http://dx.doi.org/10.1517/17460441.2016.1160051

Ejemplares similares

A Review of Vilazodone, Serotonin, and Major Depressive Disorder
por: Pierz, Kerri A., et al.
Publicado: (2014)

Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression
por: Khan, Arif, et al.
Publicado: (2014)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Clinical Relevance of Vilazodone Treatment in Patients With Major Depressive Disorder: Categorical Improvement in Symptoms
por: Culpepper, Larry, et al.
Publicado: (2014)

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2014)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang, Xiao-Fei, et al.
Publicado: (2015)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats
por: Oosting, Ronald S., et al.
Publicado: (2016)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh, Mandeep, et al.
Publicado: (2012)

Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
por: Hellerstein, David J, et al.
Publicado: (2015)

A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder
por: Sinha, Shubhadeep, et al.
Publicado: (2021)

Effect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys
por: Kawata, Yoshiko, et al.
Publicado: (2020)

Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice
por: Chauhan, Mohit, et al.
Publicado: (2022)

Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects
por: Toyn, Jeremy H., et al.
Publicado: (2016)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial
por: Clayton, Anita H., et al.
Publicado: (2015)

Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB
por: Barr, David A., et al.
Publicado: (2016)

Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials
por: Shi, Ligen, et al.
Publicado: (2016)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
por: Durgam, Suresh, et al.
Publicado: (2018)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018)

Detection and characterization of drug-resistant conferring genes in Mycobacterium tuberculosis complex strains: A prospective study in two distant regions of Ghana
por: Otchere, I.D., et al.
Publicado: (2016)

Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
por: Durgam, Suresh, et al.
Publicado: (2018)

Remimazolam and Remifentanil Use Induced Severe Respiratory Depression and Laryngeal Spasm During Intravenous Sedation and Analgesia: A Case Report
por: Xin, Zhijun, et al.
Publicado: (2023)

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
por: Kim, Mimi, et al.
Publicado: (2018)

SLE clinical trials: impact of missing data on estimating treatment effects
por: Kim, Mimi, et al.
Publicado: (2019)

In vivo Metabolism of Nifurtimox and the Drug-Drug Interaction Potential Including its Major Metabolites
por: Schulz, Simone I., et al.
Publicado: (2023)

Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents
por: Lougheed, Kathryn E.A., et al.
Publicado: (2011)

Baicalein inhibits non‐small‐cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment
por: Zhang, Xiaolong, et al.
Publicado: (2020)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells
por: Ohgino, Keiko, et al.
Publicado: (2020)

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine
por: Komoto, Kana, et al.
Publicado: (2020)

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells
por: Yokogawa, Tatsushi, et al.
Publicado: (2020)

Extracting Atomic Contributions to Binding Free Energy using Molecular Dynamics Simulations with Mixed Solvents (MDmix)
por: Alvarez-Garcia, Daniel, et al.
Publicado: (2022)

Event Monitoring and Evaluation by Community Pharmacists in Japan: A Pilot Study on Fenofibrate and Pemafibrate
por: Takahashi, Masao, et al.
Publicado: (2022)

Key Targets and Molecular Mechanisms of Active Volatile Components of Rabdosia rubescens in Gastric Cancer Cells
por: Hu, Yanhui, et al.
Publicado: (2022)

Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study
por: Kadam, Renuka L., et al.
Publicado: (2020)

Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial
por: Citrome, Leslie, et al.
Publicado: (2015)

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Mathews, Maju, et al.
Publicado: (2015)

Randomized trial of vilazodone versus sertraline in depression: Concerns and comments
por: Praharaj, Samir Kumar
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_47sb55e6pkriegffi9jhcod69r